Acute and Critical Care

Case Report

Pulmonary
Successful Treatment with Empirical Erlotinib in a Patient with Respiratory Failure Caused by Extensive Lung Adenocarcinoma: Suk Hyeon Jeong, Sang-Won Um, Hyun Lee, Kyeongman Jeon, Kyung Jong Lee, Gee Young Suh, Man Pyo Chung, Hojoong Kim, O Jung Kwon, Yoon La Choi; Korean J Crit Care Med. 2016;31(1):44-48. Published online February 29, 2016; DOI: https://doi.org/10.4266/kjccm.2016.31.1.44

5,529 View
82 Download
2 Crossref

We herein describe a 70-year-old woman who presented with respiratory failure due to extensive lung adenocarcinoma. Despite advanced disease, care in the intensive care unit with ventilator support was performed because she was a newly diagnosed patient and was considered to have the potential to recover after cancer treatment. Because prompt control of the cancer was needed to treat the respiratory failure, empirical treatment with an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor was initiated before confirmation of EGFR-mutant adenocarcinoma, and the patient was successfully treated. Later, EGFR-mutant adenocarcinoma was confirmed.

Citations

Citations to this article as recorded by

Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report
Shreya Bhatia, Manuel G. Cortez, Spencer Lessans, Wade T. Iams
Oncotarget.2024; 15(1): 27. CrossRef
Lung cancer with superior vena cava syndrome diagnosed by intravascular biopsy using EBUS-TBNA
Daegeun Lee, Seong Mi Moon, Dongwuk Kim, Juwon Kim, Haseong Chang, Bumhee Yang, Suk Hyeon Jeong, Kyung Jong Lee
Respiratory Medicine Case Reports.2016; 19: 177. CrossRef

Original Article

Effect of the Neutrophil Elastase Inhibitor on Acute Lung Injury after Pulmonary Resection for Lung Cancer: A Preliminary Study: So Young Park, Sunghoon Park, Kyeongman Jeon, So Yeon Lim, Maeng Real Park, Sueah Kim, Jae Uk Song, Jhin Gook Kim, O Jung Kwon, Gee Young Suh; Korean J Crit Care Med. 2009;24(3):124-128.; DOI: https://doi.org/10.4266/kjccm.2009.24.3.124

2,772 View
22 Download

Abstract PDF: BACKGROUND
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the leading causes of death after lungresection. Neutrophil elastase is thought to be an important mediator in the pathogenesis of ALI. Sivelestat is a new neutrophil elastase inhibitor which may improve the outcome in patients with ALI/ARDS after lung resection. The objective of this study was to determine whether or not sivelestat can reduce mortality in patients with ALI after pulmonary resection for lung cancer.
METHODS
This study was a retrospective case-control study of twenty three patients who developed ALI/ARDS within seven days of lung resection for lung cancer. The control group (n = 12) received standard care, while the sivelestat group (n = 11) received a continuous infusion of sivelestat (0.2 mg/kg/hr) for seven days in addition to standard care.
RESULTS
There was no significant difference in the baseline characteristics between the control and sivelestat groups, except for heart rate. Six of twelve patients (50%) in the control group survived, while seven of twelve patients (64%) survived in the sivelestat group (p = 0.34). There was also no significant difference between the two groups in the progression to ARDS. In the sivelelestat group, survivors had lower APACHE II and SOFA scores than the patients in the control group.
CONCLUSIONS
There was no additional effect of a neutrophil elastase inhibitor in the treatment of ALI after pulmonary resection for lung cancer.

First
Prev
Page of 1
Next
Last

Search